Novartis Purchases Bristol's Consumer Business
This article was originally published in The Pink Sheet Daily
Executive Summary
The $660 mil. acquisition makes the Swiss firm a "more attractive" Rx-to-OTC switch partner, Novartis Consumer Health CEO Choffat says. Bristol's OTCs include Excedrin, Comtrex, Bufferin, No-Doz.
You may also be interested in...
Bristol On Track For Growth In 2007 Despite Pargluva Setback
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.
Bristol On Track For Growth In 2007 Despite Pargluva Setback
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.
Second Quarter Earnings Season Heats Up
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: